NCT00538109已完成不适用
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8
- 主要终点
- Effectiveness
研究概览
简要总结
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients with Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Imatinib (Glivec/Gleevec) Resistant or Intolerant CML in Blast Crisis, Accelerated Phase or Chronic Phase
排除标准
- 未提供
结局指标
主要结局
Effectiveness
时间窗: overall
次要结局
未报告次要终点
研究者
Dr. Naeem A. Chaudhri
Principal Investigator
King Faisal Specialist Hospital & Research Center
相似试验
已完成
4 期
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 TrialChronic Myelogenous LeukemiaNCT01368523Novartis Pharmaceuticals19
进行中（未招募）
不适用
An open-label, single center study of oral AMN 107 (nilotinib) in adult patients with imatinib - resistant or - intolerant chronic myeloid leukemia in chronic phase, accelerated phase or blast crisis, previously enrolled in and having completed ENACT (CAMN107A2109) trial in Hungary.adult patients with imatinib - resistant or - intolerant CML-CP, CML-AP or CML-BCEUCTR2008-004467-19-HUovartis Hungary Ltd
已完成
3 期
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic PhaseLeukemiaNCT02272777Novartis Pharmaceuticals225
No Longer Available
不适用
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid LeukemiaChronic Myeloid LeukemiaNCT00302016Novartis Pharmaceuticals
No Longer Available
不适用
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or IntolerantChronic Myelogenous LeukemiaNCT00413270Novartis Pharmaceuticals